BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Files An 8-K Other Events
Item 8.01. Other Information.

On March15, 2018, BioDelivery Sciences International, Inc. (the “Company”) issued a press release announcing the Company filed its Annual Report on Form 10-K for the year ended December31, 2017 and providing an update on the Company’s business operations, financial results and anticipated milestones for the year 2018. A copy of such press release is attached as Exhibit 99.1 hereto.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K, the press release included herein (and the conference call referred to in such press release), and any statements of representatives and partners of the Company related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the results of the Company’s commercialization programs for BELBUCA^®, BUNAVAIL^® and ONSOLIS^®) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

ONSOLIS^®, BUNAVAIL^® and BELBUCA^®are registered trademarks of the Company.BUNAVAIL and BELBUCA logos are trademarks owned by the Company. All other trademarks and tradenames are owned by their respective owners.

BIODELIVERY SCIENCES INTERNATIONAL INC Exhibit
EX-99.1 2 d551274dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update Full-year 2017 net revenue of $62.0 million vs. $15.5 million in 2016 BELBUCA® fourth quarter 2017 net revenue of $9.4 million vs. $6.4 million in third quarter; an increase of 47% BELBUCA prescription growth of 84% in 2017 over 2016 Preferred coverage for BELBUCA secured with Humana,…
To view the full exhibit click here

About BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.